Objective To study the inhibiting effect of Octreotide combined with Omeprazole on hepatoma H22. Methods The hepatoma H22 model of the subcutaneous transplanted tumor was established, and then mices bearing tumor were divided into 5 groups randomly: control group; Cisplatine goup; Octreotide group; Omeprazole group; Octreotide+Omeprazole group (combined treatment group), they were treated with different drugs. The tumor inhibition and the micro vessel density (MVD) of hepatoma H22 in different groups were all detected after administration. Results The tumor inhibiting rate was 33.5% in Octreotide group, 29.6% in Omeprazole group and 37.1% in combined treatment group respectively, there were significant differences (P > 0.05). The MVD of Octreotide group, Omeprazole group and combined treatment group were respectively (29.34±8.78), (40.95±9.23), (23.89±5.76), and there were significant differences (P < 0.05) compared with control group. Conclusion The inhibition effect on tumor growth of Octreotide combined with Omeprazole is stronger than that of each drug singly, and there may be a synergic anticancer effect on hepatoma H22.%目的 观察奥曲肽与奥美拉唑联合应用对肝癌H22生长的抑制作用.方法 建立小鼠肝癌H22肉瘤移植模型后,随机分为阴性对照组、顺铂组、奥曲肽组、奥美拉唑组和奥曲肽+奥美拉唑组(联合用药组),给药后计算肿瘤生长抑制率和肿瘤微血管密度的变化.结果 奥曲肽组与奥美拉唑组的抑瘤率分别为33.5%、29.6%,联合用药组的抑瘤率为37.1%,差异无统计学意义(P ＞ 0.05).与阴性对照组比较,奥曲肽组与奥美拉唑组能够降低小鼠肝癌H22的微血管密度,差异有统计学意义(P ＜ 0.05),联合用药降低更加明显,其中奥曲肽组与奥美拉唑组的微血管密度分别为(29.34±8.78)、(40.95±9.23),联合用药组为(23.89±5.76).结论 奥曲肽联合奥美拉唑能够显著抑制肝癌H22的生长,联合用药可能具有协同效果.
展开▼
